Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice.

Cao M, Royce DB, Risingsong R, Williams CR, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2016 Jan;9(1):105-14. doi: 10.1158/1940-6207.CAPR-15-0325. Epub 2015 Nov 10.

2.

Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT.

Carcinogenesis. 2015 Jul;36(7):769-81. doi: 10.1093/carcin/bgv061. Epub 2015 May 4.

3.

The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2014 Jul;7(7):698-707. doi: 10.1158/1940-6207.CAPR-14-0047. Epub 2014 May 9.

4.

The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.

Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT.

Carcinogenesis. 2013 Jan;34(1):199-210. doi: 10.1093/carcin/bgs319. Epub 2012 Oct 6.

5.

The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice.

Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K.

Cancer Prev Res (Phila). 2012 May;5(5):726-34. doi: 10.1158/1940-6207.CAPR-11-0404. Epub 2012 Mar 8.

6.

CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.

Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT.

Cancer Prev Res (Phila). 2012 Jan;5(1):89-97. doi: 10.1158/1940-6207.CAPR-11-0359. Epub 2011 Sep 20.

7.

Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis.

Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, Liby KT, Risingsong R, Sporn M, Beal MF, Kiaei M.

Free Radic Biol Med. 2011 Jul 1;51(1):88-96. doi: 10.1016/j.freeradbiomed.2011.03.027. Epub 2011 Mar 30.

8.

Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.

Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB.

Cancer Prev Res (Phila). 2010 Nov;3(11):1427-34. doi: 10.1158/1940-6207.CAPR-10-0197. Epub 2010 Oct 19.

9.

Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.

Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM, Sporn MB.

Cancer Prev Res (Phila). 2009 Dec;2(12):1050-8. doi: 10.1158/1940-6207.CAPR-09-0085. Epub 2009 Dec 1.

10.

Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, Beal MF.

PLoS One. 2009 Jun 1;4(6):e5757. doi: 10.1371/journal.pone.0005757.

11.

A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin.

Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, Groopman JD, Kensler TW, Sporn MB.

Cancer Res. 2008 Aug 15;68(16):6727-33. doi: 10.1158/0008-5472.CAN-08-1123.

12.

Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.

Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB.

Clin Cancer Res. 2008 Jul 15;14(14):4556-63. doi: 10.1158/1078-0432.CCR-08-0040.

13.

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.

Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB.

Mol Cancer Ther. 2008 May;7(5):1251-7. doi: 10.1158/1535-7163.MCT-08-0023.

14.

A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland.

Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA, Sporn MB.

Clin Cancer Res. 2007 Oct 15;13(20):6237-43.

15.

Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities.

Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB.

Mol Cancer Ther. 2007 Jul;6(7):2113-9.

16.

The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB.

Cancer Res. 2007 Mar 15;67(6):2414-9.

17.

The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.

Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB.

Clin Cancer Res. 2006 Oct 1;12(19):5902-9.

18.

Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A.

Honda T, Liby KT, Su X, Sundararajan C, Honda Y, Suh N, Risingsong R, Williams CR, Royce DB, Sporn MB, Gribble GW.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6306-9. Epub 2006 Sep 25.

19.

The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.

Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4288-93.

20.

The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.

Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB.

Cancer Res. 2005 Jun 1;65(11):4789-98.

21.

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.

Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P.

Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4584-9. Epub 2005 Mar 14.

22.

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.

Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB.

Cancer Res. 2004 May 15;64(10):3566-71.

23.

The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.

Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB.

Clin Cancer Res. 2003 Jul;9(7):2798-806.

24.

Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.

Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB.

Cancer Res. 2003 Mar 15;63(6):1371-6.

25.

Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages.

Favaloro FG Jr, Honda T, Honda Y, Gribble GW, Suh N, Risingsong R, Sporn MB.

J Med Chem. 2002 Oct 24;45(22):4801-5.

PMID:
12383005
26.

Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.

Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, Risingsong R, Farris MR, Heyman RA, Sporn MB.

Clin Cancer Res. 2002 Oct;8(10):3270-5.

27.

A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.

Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB.

Cancer Res. 1999 Nov 15;59(22):5671-3.

Supplemental Content

Loading ...
Support Center